Gemcitabine-cisplatin: A schedule finding study

J. R. Kroep, G. J. Peters, C. J A Van Moorsel, A. Çatik, J. B. Vermorken, H. M. Pinedo, C. J. Van Groeningen

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the tolerability of four alternating cisplatin- gemcitabine schedules. A secondary aim was to evaluate the clinical efficacy of this combination. Patients and methods: Forty-one patients with advanced solid tumors received alternating sequences with a 4- and 24-hour interval of cisplatin and gemcitabine. Gemcitabine 800 mg/m2 was administered as a 30- min infusion on day 1, 8 and 15, and cisplatin 50 mg/m2 over 1 hour on day 1 and 8; in case of the 24-hour time interval the second drug was administered one day later. Four cisplatin-gemcitabine schedules were studied: gemcitabine four hour before cisplatin (10 patients), or vice versa (14 patients) and gemcitabine twenty-four hours before cisplatin (9 patients) or vice versa (8 patients). The sequence of drug administration was reversed in the second cycle of therapy in each individual patient, enabling the evaluation of sequence-dependent side effects. Twenty-six patients had received prior chemotherapy, of which twenty-one platinum-based. Results: The main toxicity was myelosuppression. Overall, grade 3 and 4 thrombocytopenia was observed in 27 out of 41 patients (66%) and was not schedule dependent. No serious bleeding occurred. Leukopenia was significantly different between the 4 alternating schedules (P = 0.01); gemcitabine 24 hours before cisplatin was significantly less toxic compared to both cisplatin 4 hours and 24 hours before gemcitabine (P = 0.01 and P = 0.003, respectively). Furthermore, paired analysis of the 4-hour and 24-hour data sets showed that leukopenia was significantly more serious when cisplatin preceded gemcitabine (P = 0.005). Although most patients received prior treatment, both prior chemotherapy and radiotherapy were not related to toxicity. Overall, grade 3 and 4 leukopenia Occurred in 19 out of 41 patients (46%). Anemia (Hb ≤ 6.0 mmol/l) was not sequence dependent and was observed in 63% of patients. Myelotoxicity was cumulative between cycles and caused frequent omission of gemcitabine on day 15. Overall, in 51% of administered cycles there was no omission of gemcitabine. A mean of 3.5 therapy cycles was administered. Nonhematological toxicity was moderate, consisting mainly of grade 1 and 2 nausea/vomiting and fatigue, and was not schedule dependent. Recently, we described that the schedule in which cisplatin was administered 24 hours before gemcitabine produced the best pharmacological profile. Based on this and because toxicity WaS manageable, the schedule cisplatin 24 hours prior to gemcitabine was chosen for phase II evaluation. Nine out of thirty-six evaluable patients had an objective response. These responses were observed in head and neck squamous-cell carcinoma (HNSCC), non-small-cell lung cancer (NSCLC), melanoma, adenocarcinoma of unknown origin, ovarian and esophageal carcinoma. Conclusions: Myelosuppression was the most important toxicity. Leukopenia was schedule dependent: gemcitabine before cisplatin was less toxic than the reversed sequence, in this respect. Some encouraging responses were seen in patients with esophageal cancer. Currently, a phase II study with cisplatin 24 hours before gemcitabine is ongoing in patients with advanced upper gastro-intestinal tumors.

Original languageEnglish (US)
Pages (from-to)1503-1510
Number of pages8
JournalAnnals of Oncology
Volume10
Issue number12
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

gemcitabine
Cisplatin
Appointments and Schedules
Leukopenia
Poisons

Keywords

  • Cisplatin
  • Esophageal cancer
  • Gemcitabine
  • Schedule dependency

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kroep, J. R., Peters, G. J., Van Moorsel, C. J. A., Çatik, A., Vermorken, J. B., Pinedo, H. M., & Van Groeningen, C. J. (1999). Gemcitabine-cisplatin: A schedule finding study. Annals of Oncology, 10(12), 1503-1510. https://doi.org/10.1023/A:1008339425708

Gemcitabine-cisplatin : A schedule finding study. / Kroep, J. R.; Peters, G. J.; Van Moorsel, C. J A; Çatik, A.; Vermorken, J. B.; Pinedo, H. M.; Van Groeningen, C. J.

In: Annals of Oncology, Vol. 10, No. 12, 1999, p. 1503-1510.

Research output: Contribution to journalArticle

Kroep, JR, Peters, GJ, Van Moorsel, CJA, Çatik, A, Vermorken, JB, Pinedo, HM & Van Groeningen, CJ 1999, 'Gemcitabine-cisplatin: A schedule finding study', Annals of Oncology, vol. 10, no. 12, pp. 1503-1510. https://doi.org/10.1023/A:1008339425708
Kroep JR, Peters GJ, Van Moorsel CJA, Çatik A, Vermorken JB, Pinedo HM et al. Gemcitabine-cisplatin: A schedule finding study. Annals of Oncology. 1999;10(12):1503-1510. https://doi.org/10.1023/A:1008339425708
Kroep, J. R. ; Peters, G. J. ; Van Moorsel, C. J A ; Çatik, A. ; Vermorken, J. B. ; Pinedo, H. M. ; Van Groeningen, C. J. / Gemcitabine-cisplatin : A schedule finding study. In: Annals of Oncology. 1999 ; Vol. 10, No. 12. pp. 1503-1510.
@article{8dc27c877b4a4d60916eb54f82cce27f,
title = "Gemcitabine-cisplatin: A schedule finding study",
abstract = "Purpose: To evaluate the tolerability of four alternating cisplatin- gemcitabine schedules. A secondary aim was to evaluate the clinical efficacy of this combination. Patients and methods: Forty-one patients with advanced solid tumors received alternating sequences with a 4- and 24-hour interval of cisplatin and gemcitabine. Gemcitabine 800 mg/m2 was administered as a 30- min infusion on day 1, 8 and 15, and cisplatin 50 mg/m2 over 1 hour on day 1 and 8; in case of the 24-hour time interval the second drug was administered one day later. Four cisplatin-gemcitabine schedules were studied: gemcitabine four hour before cisplatin (10 patients), or vice versa (14 patients) and gemcitabine twenty-four hours before cisplatin (9 patients) or vice versa (8 patients). The sequence of drug administration was reversed in the second cycle of therapy in each individual patient, enabling the evaluation of sequence-dependent side effects. Twenty-six patients had received prior chemotherapy, of which twenty-one platinum-based. Results: The main toxicity was myelosuppression. Overall, grade 3 and 4 thrombocytopenia was observed in 27 out of 41 patients (66{\%}) and was not schedule dependent. No serious bleeding occurred. Leukopenia was significantly different between the 4 alternating schedules (P = 0.01); gemcitabine 24 hours before cisplatin was significantly less toxic compared to both cisplatin 4 hours and 24 hours before gemcitabine (P = 0.01 and P = 0.003, respectively). Furthermore, paired analysis of the 4-hour and 24-hour data sets showed that leukopenia was significantly more serious when cisplatin preceded gemcitabine (P = 0.005). Although most patients received prior treatment, both prior chemotherapy and radiotherapy were not related to toxicity. Overall, grade 3 and 4 leukopenia Occurred in 19 out of 41 patients (46{\%}). Anemia (Hb ≤ 6.0 mmol/l) was not sequence dependent and was observed in 63{\%} of patients. Myelotoxicity was cumulative between cycles and caused frequent omission of gemcitabine on day 15. Overall, in 51{\%} of administered cycles there was no omission of gemcitabine. A mean of 3.5 therapy cycles was administered. Nonhematological toxicity was moderate, consisting mainly of grade 1 and 2 nausea/vomiting and fatigue, and was not schedule dependent. Recently, we described that the schedule in which cisplatin was administered 24 hours before gemcitabine produced the best pharmacological profile. Based on this and because toxicity WaS manageable, the schedule cisplatin 24 hours prior to gemcitabine was chosen for phase II evaluation. Nine out of thirty-six evaluable patients had an objective response. These responses were observed in head and neck squamous-cell carcinoma (HNSCC), non-small-cell lung cancer (NSCLC), melanoma, adenocarcinoma of unknown origin, ovarian and esophageal carcinoma. Conclusions: Myelosuppression was the most important toxicity. Leukopenia was schedule dependent: gemcitabine before cisplatin was less toxic than the reversed sequence, in this respect. Some encouraging responses were seen in patients with esophageal cancer. Currently, a phase II study with cisplatin 24 hours before gemcitabine is ongoing in patients with advanced upper gastro-intestinal tumors.",
keywords = "Cisplatin, Esophageal cancer, Gemcitabine, Schedule dependency",
author = "Kroep, {J. R.} and Peters, {G. J.} and {Van Moorsel}, {C. J A} and A. {\cC}atik and Vermorken, {J. B.} and Pinedo, {H. M.} and {Van Groeningen}, {C. J.}",
year = "1999",
doi = "10.1023/A:1008339425708",
language = "English (US)",
volume = "10",
pages = "1503--1510",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Gemcitabine-cisplatin

T2 - A schedule finding study

AU - Kroep, J. R.

AU - Peters, G. J.

AU - Van Moorsel, C. J A

AU - Çatik, A.

AU - Vermorken, J. B.

AU - Pinedo, H. M.

AU - Van Groeningen, C. J.

PY - 1999

Y1 - 1999

N2 - Purpose: To evaluate the tolerability of four alternating cisplatin- gemcitabine schedules. A secondary aim was to evaluate the clinical efficacy of this combination. Patients and methods: Forty-one patients with advanced solid tumors received alternating sequences with a 4- and 24-hour interval of cisplatin and gemcitabine. Gemcitabine 800 mg/m2 was administered as a 30- min infusion on day 1, 8 and 15, and cisplatin 50 mg/m2 over 1 hour on day 1 and 8; in case of the 24-hour time interval the second drug was administered one day later. Four cisplatin-gemcitabine schedules were studied: gemcitabine four hour before cisplatin (10 patients), or vice versa (14 patients) and gemcitabine twenty-four hours before cisplatin (9 patients) or vice versa (8 patients). The sequence of drug administration was reversed in the second cycle of therapy in each individual patient, enabling the evaluation of sequence-dependent side effects. Twenty-six patients had received prior chemotherapy, of which twenty-one platinum-based. Results: The main toxicity was myelosuppression. Overall, grade 3 and 4 thrombocytopenia was observed in 27 out of 41 patients (66%) and was not schedule dependent. No serious bleeding occurred. Leukopenia was significantly different between the 4 alternating schedules (P = 0.01); gemcitabine 24 hours before cisplatin was significantly less toxic compared to both cisplatin 4 hours and 24 hours before gemcitabine (P = 0.01 and P = 0.003, respectively). Furthermore, paired analysis of the 4-hour and 24-hour data sets showed that leukopenia was significantly more serious when cisplatin preceded gemcitabine (P = 0.005). Although most patients received prior treatment, both prior chemotherapy and radiotherapy were not related to toxicity. Overall, grade 3 and 4 leukopenia Occurred in 19 out of 41 patients (46%). Anemia (Hb ≤ 6.0 mmol/l) was not sequence dependent and was observed in 63% of patients. Myelotoxicity was cumulative between cycles and caused frequent omission of gemcitabine on day 15. Overall, in 51% of administered cycles there was no omission of gemcitabine. A mean of 3.5 therapy cycles was administered. Nonhematological toxicity was moderate, consisting mainly of grade 1 and 2 nausea/vomiting and fatigue, and was not schedule dependent. Recently, we described that the schedule in which cisplatin was administered 24 hours before gemcitabine produced the best pharmacological profile. Based on this and because toxicity WaS manageable, the schedule cisplatin 24 hours prior to gemcitabine was chosen for phase II evaluation. Nine out of thirty-six evaluable patients had an objective response. These responses were observed in head and neck squamous-cell carcinoma (HNSCC), non-small-cell lung cancer (NSCLC), melanoma, adenocarcinoma of unknown origin, ovarian and esophageal carcinoma. Conclusions: Myelosuppression was the most important toxicity. Leukopenia was schedule dependent: gemcitabine before cisplatin was less toxic than the reversed sequence, in this respect. Some encouraging responses were seen in patients with esophageal cancer. Currently, a phase II study with cisplatin 24 hours before gemcitabine is ongoing in patients with advanced upper gastro-intestinal tumors.

AB - Purpose: To evaluate the tolerability of four alternating cisplatin- gemcitabine schedules. A secondary aim was to evaluate the clinical efficacy of this combination. Patients and methods: Forty-one patients with advanced solid tumors received alternating sequences with a 4- and 24-hour interval of cisplatin and gemcitabine. Gemcitabine 800 mg/m2 was administered as a 30- min infusion on day 1, 8 and 15, and cisplatin 50 mg/m2 over 1 hour on day 1 and 8; in case of the 24-hour time interval the second drug was administered one day later. Four cisplatin-gemcitabine schedules were studied: gemcitabine four hour before cisplatin (10 patients), or vice versa (14 patients) and gemcitabine twenty-four hours before cisplatin (9 patients) or vice versa (8 patients). The sequence of drug administration was reversed in the second cycle of therapy in each individual patient, enabling the evaluation of sequence-dependent side effects. Twenty-six patients had received prior chemotherapy, of which twenty-one platinum-based. Results: The main toxicity was myelosuppression. Overall, grade 3 and 4 thrombocytopenia was observed in 27 out of 41 patients (66%) and was not schedule dependent. No serious bleeding occurred. Leukopenia was significantly different between the 4 alternating schedules (P = 0.01); gemcitabine 24 hours before cisplatin was significantly less toxic compared to both cisplatin 4 hours and 24 hours before gemcitabine (P = 0.01 and P = 0.003, respectively). Furthermore, paired analysis of the 4-hour and 24-hour data sets showed that leukopenia was significantly more serious when cisplatin preceded gemcitabine (P = 0.005). Although most patients received prior treatment, both prior chemotherapy and radiotherapy were not related to toxicity. Overall, grade 3 and 4 leukopenia Occurred in 19 out of 41 patients (46%). Anemia (Hb ≤ 6.0 mmol/l) was not sequence dependent and was observed in 63% of patients. Myelotoxicity was cumulative between cycles and caused frequent omission of gemcitabine on day 15. Overall, in 51% of administered cycles there was no omission of gemcitabine. A mean of 3.5 therapy cycles was administered. Nonhematological toxicity was moderate, consisting mainly of grade 1 and 2 nausea/vomiting and fatigue, and was not schedule dependent. Recently, we described that the schedule in which cisplatin was administered 24 hours before gemcitabine produced the best pharmacological profile. Based on this and because toxicity WaS manageable, the schedule cisplatin 24 hours prior to gemcitabine was chosen for phase II evaluation. Nine out of thirty-six evaluable patients had an objective response. These responses were observed in head and neck squamous-cell carcinoma (HNSCC), non-small-cell lung cancer (NSCLC), melanoma, adenocarcinoma of unknown origin, ovarian and esophageal carcinoma. Conclusions: Myelosuppression was the most important toxicity. Leukopenia was schedule dependent: gemcitabine before cisplatin was less toxic than the reversed sequence, in this respect. Some encouraging responses were seen in patients with esophageal cancer. Currently, a phase II study with cisplatin 24 hours before gemcitabine is ongoing in patients with advanced upper gastro-intestinal tumors.

KW - Cisplatin

KW - Esophageal cancer

KW - Gemcitabine

KW - Schedule dependency

UR - http://www.scopus.com/inward/record.url?scp=0033384755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033384755&partnerID=8YFLogxK

U2 - 10.1023/A:1008339425708

DO - 10.1023/A:1008339425708

M3 - Article

C2 - 10643544

AN - SCOPUS:0033384755

VL - 10

SP - 1503

EP - 1510

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -